
Get Instant Solution By an Expert Advisor
(4.8)

India’s medical device regulatory framework continues to evolve, and the 2026 update to device classification brings important clarifications for manufacturers, importers, and distributors. The Central Drugs Standard Control Organization (CDSCO), operating under the Ministry of Health and Family Welfare, is responsible for regulating medical devices in India. With growing innovation in digital health, AI-based tools, and implantable technologies, correct classification has become more critical than ever.
Medical devices in India are regulated under the Drugs and Cosmetics Act and the Medical Devices Rules (MDR 2017). The Medical Devices Rules introduced a risk-based classification system, aligning India with global regulatory practices followed in the EU and other jurisdictions. The 2026 update further refines classification guidelines, especially for software-driven devices and emerging technologies.
What is CDSCO Medical Device Import Certificate?
Classification determines the level of regulatory control applied to a device. The higher the risk associated with the device, the stricter the regulatory requirements.
Under CDSCO, medical devices are categorized into four classes:
The classification is based on factors such as the following:
These devices pose minimal potential harm to users.
Examples:
Class A manufacturers are subject to basic quality management requirements but face relatively simplified approvals.
These devices carry slightly higher risk and require closer oversight.
Examples:
Class B devices require more documentation and inspection compared to Class A.
These devices may have a significant impact on patient health.
Examples:
These are life-supporting or life-sustaining devices with the highest level of regulatory scrutiny.
Examples:
The 2026 update focuses on modern healthcare technologies and clarity in classification rules.
Software as a Medical Device (SaMD) has received greater regulatory clarity. AI-driven diagnostic tools, health monitoring apps with clinical claims, and machine learning imaging software are now clearly categorized under risk-based rules depending on the following:
This update ensures that digital health products are not left in regulatory gray areas.
CDSCO has refined interpretation notes in the First Schedule of MDR 2017. These clarifications help manufacturers better determine whether their device falls under invasive, non-invasive, active, or special rules categories.
Misclassification can lead to penalties, so these clarifications reduce compliance uncertainty.
The 2026 revision strongly reinforces that intended use determines classification. Marketing claims, labeling, instructions for use, and promotional materials must align with the chosen risk category.
Even minor wording changes can shift a device from Class B to Class C if it suggests diagnostic or life-supporting functionality.
Higher-class devices now face stricter vigilance reporting timelines. Manufacturers must maintain:
CDSCO Certificate Registration in Delhi: Documents, Process, and Fees
The licensing authority depends on the device class:
This distinction affects documentation, approval timelines, and regulatory interactions.
For manufacturers:
For importers:
Incorrect classification can result in:
Over-classification may increase compliance costs unnecessarily, while under-classification can expose businesses to serious regulatory risks. A proper regulatory strategy involves technical review, regulatory consultation, and careful evaluation of intended use statements.
To ensure smooth approval under updated rules:
For AI and digital device manufacturers, early regulatory consultation is strongly recommended due to evolving interpretations.
The CDSCO Classification of Medical Devices (2026 Update) represents India’s continued move toward a robust, globally aligned regulatory system. By refining risk categorization, expanding software oversight, and strengthening post-market monitoring, CDSCO aims to improve patient safety while supporting innovation.
Nishi Chawla
25 Apr, 2026
Nishi Chawla
25 Apr, 2026
Nishi Chawla
25 Apr, 2026
Nishi Chawla
24 Apr, 2026
Nishi Chawla
23 Apr, 2026
Get Instant Solution By an Expert Advisor
(4.8)
We simplify compliance through a proven 4-step process: Consultation, Documentation, Submission, and certification. From understanding requirements to getting final approvals, we deliver a smooth, timely, and fully compliant journey for your business.
What our customer says about us
Leave a Reply
Your email address will not be published. Required fields are marked *